The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice

• Published in: Dose-response 2020-04, Vol.18 (2), p.155932582093129-1559325820931292
• Main Authors: Sun, Hao, Cai, Hui, Fu, Yue, Wang, Qin, Ji, Kaihua, Du, Liqing, Xu, Chang, Tian, Lifang, He, Ningning, Wang, Jinhan, Zhang, Manman, Liu, Yang, Wang, Yan, Li, Jia, Liu, Qiang
• Format: Article
• Language: English
• Subjects: Biomarkers; Gastric cancer; Inflammation; Inflammatory bowel disease; Polyphenols; Potential Biomarkers of Radiation Damage; Radiation therapy
• ISSN: 1559-3258; 1559-3258
• DOI: 10.1177/1559325820931292

With the extensive application of radiotherapy in various cancers, its side effects in tissues adjacent to cancers are garnering much attention. Intestines are sensitive to irradiation due to its rapid proliferation, and irradiation-induced enteric inflammation is common in patients with pelvic peritoneal tumors. Sirt1, class III protein deacetylase, could lead to transcriptional repression of various inflammation-associated genes, and our previous study has proved its relationship with interleukin (IL)-1β. Here we show that resveratrol, the activator of Sirt1, could alleviate the bowel inflammation induced by irradiation and the expression of Sirt1 is consistent with the inflammation level. We further identified in vivo that Sirt1 repress the expression of IL-1β by the repression of NLR Family, Pyrin Domain Containing protein 3 (NLRP3) expression. In conclusion, this study confirms resveratrol acts against radiation-induced inflammatory bowel disease via NLRP-3 inflammasome repression in mice and supports Sirt1 as a potential biomarker and therapy target in intestinal radiation protection.